With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy ...

Aritzia’s global ambitions and strong digital platform fuel growth, despite copycat risks and U.S. exposure. Find out why ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Research from Harvard Kennedy School’s Marcella Alsan shows Black survey respondents’ interest in clinical trials increased ...

Japan's Nikkei share average rose 1% on Friday to clock its best week in three months, as investors turned more hopeful that ...

The S&P 500 ticked 0.1% higher on Thursday, April 17, wrapping up a shortened week that focused on earnings and the Federal ...

The S&P 500 rose 0.85%, driven by gains in Eli Lilly and Apple, amid optimism over U.S.-Japan trade talks and uncertainty ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

The Trump administration has reportedly disrupted over 100 clinical trials. Science News spoke to researchers about the impacts on four of them.

American President Donald Trump and Chinese President Xi Jinping's stand-off is costing firms in both nations billions of ...